Home Business & Economics

Business & Economics

Scientist pipetting

Gilead Acquires Immunomedics – Accelerating an Emerging and Complementary Oncology Pipeline

Just ahead of World ADC, the industry meeting for anyone involved in the development, manufacturing antibody-drug conjugates, and the...

Creating a New Single-digit Nanogram Containment Manufacturing Facility: MilliporeSigma Announces US $65 M Investment...

In a statement today, MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, confirmed a US $65 million...

Exelixis and Catalent to Jointly Develop Multiple SMARTag®-based Antibody-drug Conjugates

Alameda- (California-) based Exelixis confirmed that it has signed a partnership agreement with Catalent to develop multiple antibody-drug conjugates...

NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple Targets

Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for...

ADC Therapeutics On Track to File BLA for Loncastuximab Tesirine for R/R DLBCL later...

This week Swiss-based ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for...

Daiichi Sankyo and AstraZeneca to Jointly Evaluate Patritumab Deruxtecan + Osimertinib in EGFR-Mutated...

Earlier this week Daiichi Sankyo and AstraZeneca confirmed that the companies had entered into a clinical trial collaboration with...

U.S. FDA Approves Belantamab Mafodotin as a Monotherapy in R/R Multiple Myeloma

The U.S. Food and Drug Administration has approved* belantamab mafodotin-blmf (Blenrep®; GlaxoSmithKline/GSK) as a monotherapy treatment for adult patients...

Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement

Piramal Pharma Solutions, a contract development and manufacturing organization (CDMO) and San Francisco-based biotech Bolt Bioterapeutics have signed a...

Daiichi Sankyo and AstraZeneca Agree on Global Development and Commercialization for DS-1062

Daiichi Sankyo and AstraZeneca confirmed entering into a global development and commercialization agreement for datopotamab deruxtecan also know as...

Tubulis Closes a € 10.7 Million Series A financing to Accelerate ADC Development

Tubulis, which spun out in 2019 from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin and the Ludwig Maximilians...